MedTrace Logo

Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery

NCT00840918 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2019-03-29

No results posted yet for this study

Summary

This study is being done to determine if lidocaine, administered during surgery and for 24 hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation and 30 day mortality after surgery. Participants undergoing cardiac surgery will be randomized to receive either lidocaine or placebo.

Conditions

Interventions

DRUG

Lidocaine

Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.

OTHER

Placebo

Placebo is administered intravenously throughout surgery and during the 24 hours following surgery

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Martin Grady, M.D. · The Cleveland Clinic

  • Daniel I Sessler, M.D. · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2014-12-15
Completion
2014-12-15

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00840918 on ClinicalTrials.gov